INNO-206 - CAS 1361644-26-9
  1. Home
  2. Products
  3. ADCs Cytotoxin
  4. Daunorubicins/Doxorubicins
  5. INNO-206

INNO-206 - CAS 1361644-26-9 Catalog number: BADC-00027

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

INNO-206 (Aldoxorubicin) is the 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity.

Category
ADCs Cytotoxin
Product Name
INNO-206
CAS
1361644-26-9
Catalog Number
BADC-00027
Molecular Formula
C37H42N4O13
Molecular Weight
750.75
Purity
>98%
INNO-206

Ordering Information

Catalog Number Size Price Quantity
BADC-00027 -- $-- Inquiry

Featured Recommendations

Recommended Services
ADC Linkers Development Antibody Modification and Conjugation Technologies ADC Analysis and Characterization ADC Linker and Cytotoxin Conjugations ADC Payloads Development ADC Manufacture ADC Development for Targets ADC Development Platform
Other Types of Cytotoxins
Auristatins Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Piericidins Pyrrolobenzodiazepines Traditional Cytotoxic Agents Others
Description
INNO-206 (Aldoxorubicin) is the 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity.
Synonyms
Doxorubicin-hydrazone-caproyl-maleimide; Aldoxorubicin; 2,5-Dihydro-2,5-dioxo-1H-pyrrole-1-hexanoic acid (2E)-2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide; 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, (2E)-2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide; INNO 206; INNO206
IUPAC Name
N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide
Canonical SMILES
CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=NNC(=O)CCCCCN6C(=O)C=CC6=O)CO)O)N)O
InChI
InChI=1S/C37H42N4O13/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8,10-11,17,20,22,27,32,42,46,48,50-51H,3-5,9,12-16,38H2,1-2H3,(H,40,43)/b39-23+/t17-,20-,22-,27-,32+,37-/m0/s1
InChIKey
OBMJQRLIQQTJLR-USGQOSEYSA-N
Density
1.60±0.1 g/cm3
Solubility
Soluble in DMSO
Index Of Refraction
1.708
LogP
3.08
PSA
271.33000
Appearance
Solid Power
Shelf Life
≥360 days if stored properly
Shipping
Room temperature, or blue ice upon request.
Storage
Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years)
Pictograms
Health Hazard
Signal Word
Danger
In Vitro
Aldoxorubicin (INNO-206) inhibited blood vessel formation and reduced multiple myeloma cell growth in a pH-dependent fashion. INNO-206 alone produced marked anti-multiple myeloma effects in vivo at doses that doxorubicin was toxic, and the combination of INNO-206 plus bortezomib produced increased anti-multiple myeloma effects compared with either agent alone. In contrast, all mice receiving bortezomib with doxorubicin or PLD died.
In Vivo
INNO-206 inhibited blood vessel formation and reduced multiple myeloma cell growth in a pH-dependent fashion. INNO-206 alone produced marked anti-multiple myeloma effects in vivo at doses that doxorubicin was toxic, and the combination of INNO-206 plus bortezomib produced increased anti-multiple myeloma effects compared with either agent alone. In contrast, all mice receiving bortezomib with doxorubicin or PLD died.
Mechanism Of Action
INNO-206 is the (6-Maleimidocaproyl) hydrazone of doxorubicin. INNO-206 is a prodrug of doxorubicin that binds endogenous albumin after administration. The bound doxorubicin is released in the acidic environment of the tumor cell through cleavage of an acid sensitive linker. In preclinical models, INNO-206 was superior to doxorubicin with regard to antitumor efficacy and toxicity.
NCT NumberCondition Or DiseasePhaseStart DateSponsorStatus
NCT01580397Pancreatic Ductal AdenocarcinomaPhase 22013-06-28CytRxCompleted
NCT02014844GlioblastomaPhase 22017-01-06CytRxCompleted
NCT01706835Advanced Solid TumorsPhase 12014-12-17CytRxCompleted
NCT02235688Metastatic Solid TumorsPhase 12017-06-07CytRxCompleted
NCT01337505Malignant Solid TumourPhase 12013-02-13CytRxCompleted
1.Anti-myeloma effects of the novel anthracycline derivative INNO-206.
Sanchez E1, Li M, Wang C, Nichols CM, Li J, Chen H, Berenson JR. Clin Cancer Res. 2012 Jul 15;18(14):3856-67. doi: 10.1158/1078-0432.CCR-11-3130. Epub 2012 May 22.
PURPOSE: Doxorubicin has shown efficacy especially in combination treatment for the treatment of multiple myeloma; however, its side effects limit its use. INNO-206 is an albumin-binding prodrug of doxorubicin, which is released from albumin under acidic conditions. Because INNO-206 has not been previously evaluated in any hematologic malignancy, we determined its anti-multiple myeloma effects.
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Calculate
The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Calculate

Related Products

Muscotoxin A
Muscotoxin A
(CAS: 1653999-47-3)
Mytoxin B
Mytoxin B
(CAS: 105049-15-8)
Daunorubicin hydrochloride
Daunorubicin hydrochloride
(CAS: 23541-50-6)
DOXO-EMCH
DOXO-EMCH
(CAS: 151038-96-9)
17-AEP-GA
17-AEP-GA
(CAS: 75747-23-8)
Dolastatin 10
Dolastatin 10
(CAS: 110417-88-4)
Historical Records: INNO-206
Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Featured Services
cGMP Grade Products

BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
Site-Specific Conjugation

BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
Linkers for Bioconjugation

BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
ADC Targets
Questions & Comments
Verification code
Send Inquiry
Verification code
Resources & Supports
Inquiry Basket
loading Loading ......
Delete selectedGo to checkout